https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3125-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3125-312014-01-01 00:00:002019-02-15 08:32:45Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-01 / Immunotherapy 2013 Oct;5(10):1039-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-01 / Immunotherapy 2013 Oct;5(10):1039-422013-10-01 00:00:002019-02-15 08:50:41Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-02 / Cancer Immunol. Immunother. 2013 Aug;62(8):1381-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-02 / Cancer Immunol. Immunother. 2013 Aug;62(8):1381-922013-06-02 00:00:002019-02-15 08:50:41Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Clin. Exp. Immunol. 2012 Nov;170(2):167-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Clin. Exp. Immunol. 2012 Nov;170(2):167-772012-11-01 00:00:002019-02-15 08:50:42Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-28 / Korean J Hematol 2012 Mar;47(1):17-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-28 / Korean J Hematol 2012 Mar;47(1):17-272012-03-28 00:00:002019-02-15 08:50:44Cellular immunotherapy using dendritic cells against multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-15 / Clin. Dev. Immunol. 2012;2012:397648
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-15 / Clin. Dev. Immunol. 2012;2012:3976482012-03-15 00:00:002019-02-15 08:50:43Immunotherapy using dendritic cells against multiple myeloma: how to improve?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-01-01 / J. Immunother. 2011 Jan;34(1):100-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-01-01 / J. Immunother. 2011 Jan;34(1):100-62011-01-01 00:00:002019-02-15 08:50:46Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-10-28 / Blood 2011 Jan;117(2):393-402
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-10-28 / Blood 2011 Jan;117(2):393-4022010-10-28 00:00:002019-02-15 08:50:45Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-07 / Br. J. Haematol. 2010 Sep;150(5):554-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-07 / Br. J. Haematol. 2010 Sep;150(5):554-642010-07-07 00:00:002019-02-15 08:50:54Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neoplasma 2010;57(5):455-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neoplasma 2010;57(5):455-642010-01-01 00:00:002019-02-15 08:50:55Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies
